1-5 of 5
Lorenza Landi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, Laura Bonanno, Xiaoyue Wang, Weng Kit Lye, Andreas Görtz, Kalliopi Andrikou, Alessandro Dal Maso, Gabriele Minuti, Maximilian Papi, Joao Victor Alessi, Alessandro Di Federico, Scott Rodig, Mark Magdi Awad, Giulio Metro, Ilaria Attili, Fabiana Vitiello, Sara Pilotto, Stefania Gori, Giulio Rossi, Simonetta Buglioni, Diana Giannarelli, Lorenza Landi
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (6): 1027–1036.
https://doi.org/10.1158/1078-0432.CCR-24-2077
Published: 17 March 2025
View article titled, MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Open the PDF for MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial in another window
Includes: Supplementary data
Journal Articles

Crizotinib in ROS1 and MET Deregulated NSCLC—Response

Lorenza Landi, Rossella Bruno, Gabriella Fontanini, Federico Cappuzzo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1775.
https://doi.org/10.1158/1078-0432.CCR-20-0026
Published: 01 April 2020
View article titled, Crizotinib in <em>ROS1</em> and <em>MET</em> Deregulated NSCLC—Response
Open the PDF for Crizotinib in <em>ROS1</em> and <em>MET</em> Deregulated NSCLC—Response in another window
Journal Articles

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis, Filippo de Marinis, Gloria Borra, Alessandro Morabito, Cesare Gridelli, Domenico Galetta, Fausto Barbieri, Francesco Grossi, Enrica Capelletto, Gabriele Minuti, Francesca Mazzoni, Claudio Verusio, Emilio Bria, Greta Alì, Rossella Bruno, Agnese Proietti, Gabriella Fontanini, Lucio Crinò, Federico Cappuzzo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (24): 7312–7319.
https://doi.org/10.1158/1078-0432.CCR-19-0994
Published: 13 December 2019
View article titled, Crizotinib in <em>MET</em>-Deregulated or <em>ROS1</em>-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Open the PDF for Crizotinib in <em>MET</em>-Deregulated or <em>ROS1</em>-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial in another window
Includes: Supplementary data
Journal Articles

HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?

Federico Cappuzzo, Lorenza Landi
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (11): 2470–2472.
https://doi.org/10.1158/1078-0432.CCR-18-0198
Published: 31 May 2018
View article titled, <em>HER2</em> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
Open the PDF for <em>HER2</em> Deregulation in Lung Cancer: Right Time to Adopt an Orphan? in another window
Journal Articles

Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer

Andrea Fontana, Luca Galli, Anna Fioravanti, Paola Orlandi, Costanza Galli, Lorenza Landi, Simona Bursi, Giacomo Allegrini, Eloise Fontana, Roberta Di Marsico, Andrea Antonuzzo, Manolo D'Arcangelo, Romano Danesi, Mario Del Tacca, Alfredo Falcone, Guido Bocci
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (15): 4954–4962.
https://doi.org/10.1158/1078-0432.CCR-08-3317
Published: 29 July 2009
View article titled, Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
Open the PDF for Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer in another window